Summary
Introduction
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data.
In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 22 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for NSCLC and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine).
Example of drugs included in this study
Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474,
Example of companies included in this study
Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik
Scope of this report
- Thorough examination of status and impact of many novel drugs in development
- Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
- Case studies on major lung cancer drugs on market and in development.
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development.
- Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
- Gain insight into the current challenges and commercial opportunities associated with lung cancer
|
